Vertex Q1 adjusted EPS beats estimates, revenue rises 8%

Vertex Pharmaceuticals

04/05/2026 21:12

Overview

U.S. biotechnology firm's Q1 revenue rose 8% yr/yr to $2.99 bln

Adjusted EPS for Q1 beat analyst expectations

Company reiterated full-year 2026 revenue guidance

Outlook

Vertex reiterates 2026 revenue guidance of $12.95 bln to $13.1 bln

Company expects at least $500 mln in 2026 non-CF product revenue

Vertex forecasts 2026 non-GAAP R&D, AIPR&D and SG&A expenses at $5.65 bln to $5.75 bln

Result Drivers

CF THERAPIES DEMAND - Co said Q1 revenue growth was mainly driven by continued strong demand for cystic fibrosis therapies, including expanded eligibility and new reimbursement agreements

NON-CF PRODUCT GROWTH - Co said diversification into sickle cell disease, beta thalassemia, and acute pain contributed to revenue gains, with CASGEVY and JOURNAVX delivering more than 25% of quarterly growth

COMMERCIAL INVESTMENT - Co said increased operating expenses were primarily due to investment in launching JOURNAVX for acute pain and building out the renal franchise led by povetacicept in IgAN

Company press release: ID:nBw46Hrssa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Beat
$4.47
$4.31 (23 Analysts)
Q1 EPS
$4.02


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 27 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Vertex Pharmaceuticals Inc is $559.50, about 32% above its May 1 closing price of $423.92

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 24 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)